2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1483B
    Urotensin II, mouse acetate 99.76%
    Urotensin II, mouse acetate is an endogenous ligand for the orphan G-protein-coupled receptor GPR14 or SENR. Urotensin II, mouse acetate is a potent vasoconstrictor. Urotensin II, mouse acetate plays a physiological role in the central nervous system.
    Urotensin II, mouse acetate
  • HY-P1516A
    Angiogenin (108-122) (TFA) 98.70%
    Angiogenin (108-122) TFA is an angiogenin peptide.
    Angiogenin (108-122) (TFA)
  • HY-P1538A
    Fibrinopeptide A, human TFA 61533-47-9 98.78%
    Fibrinopeptide A, human TFA is a 16-residue short polypeptide cleaved from fibrinogen by thrombin. Fibrinopeptide A, human locates at the NH2-termini of the Aα chain.
    Fibrinopeptide A, human TFA
  • HY-P1829A
    Angiotensin I/II (1-6) (TFA) 99.24%
    Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.
    Angiotensin I/II (1-6) (TFA)
  • HY-P2728A
    Murine Antithrombin III 98%
    Murine Antithrombin III is a blood coagulation inhibitory enzyme with high catalytic efficiency, high specificity, mild action conditions, etc., and can be used in the pharmaceutical industry, industrial production, food manufacturing, aquaculture and other industries.
    Murine Antithrombin III
  • HY-P3557A
    Mibenratide TFA 98%
    Mibenratide TFA, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide TFA can be used for heart failure research.
    Mibenratide TFA
  • HY-P4253A
    Arginyl-Glutamine TFA 99.22%
    Arginyl-Glutamine TFA is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy.
    Arginyl-Glutamine TFA
  • HY-P4683A
    (Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin acetate 99.81%
    (Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin is a potent vasopressin V1 receptor (VP V1R) antagonist. (Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin significantly decreases the mean arterial pressure (MAP) in rats.
    (Phenylac1,D-Tyr(Et)2,Lys6,Arg8,des-Gly9)-Vasopressin acetate
  • HY-P5121A
    γ-Fibrinogen 377-395 TFA 98.48%
    γ-Fibrinogen377-395 TFA is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 TFA blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 TFA can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation.
    γ-Fibrinogen 377-395 TFA
  • HY-P6023A
    D-Leu-Pro-Arg-Rh110-D-Pro TFA 98%
    D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro TFA consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be used to detect FXIa activity.
    D-Leu-Pro-Arg-Rh110-D-Pro TFA
  • HY-P6023B
    D-Leu-Pro-Arg-Rh110-D-Pro acetate 98%
    D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro acetate consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity.
    D-Leu-Pro-Arg-Rh110-D-Pro acetate
  • HY-P6365B
    APP-018 452782-06-8 99.80%
    APP-018 (D-4F) is 18 D-amino acids peptide that mimics apolipoprotein A-I (apoA-I). APP-018 improves the anti-inflammatory activity of high-density lipoprotein (HDL). APP-018 can be used in researches of cardiovascular diseases.
    APP-018
  • HY-P99560
    Tadocizumab 339086-80-5
    Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research.
    Tadocizumab
  • HY-U00044
    Anipamil 83200-10-6 99.34%
    Anipamil is a long-acting calcium channel blocker, used for the treatment of cardiovascular disease.
    Anipamil
  • HY-U00165
    Midaglizole hydrochloride 79689-25-1 99.67%
    Midaglizole hydrochloride (DG5128) is a preferential α2-adrenoceptor antagonist. Midaglizole hydrochloride (DG5128) exhibits 7.4 times higher affinity (pKi=6.28) toward α2-adrenoceptor than α1-adrenoceptor.
    Midaglizole hydrochloride
  • HY-U00175
    Pamicogrel 101001-34-7 ≥99.0%
    Pamicogrel (KBT3022) is a cyclooxygenase (COX) inhibitor.
    Pamicogrel
  • HY-U00274
    Ropitoin 56079-81-3 98.16%
    Ropitoin (TR 2985) is a novel antiarrhythmic agent.
    Ropitoin
  • HY-U00286
    5-HT2A antagonist 1 204643-75-4 98%
    5-HT2A antagonist 1 is a 5-HT2A antagonist extracted from patent US5728835A and JP 1007727. 5-HT2A antagonist 1 may be useful in treatment of gastrointestinal disorders circulatory disorders.
    5-HT2A antagonist 1
  • HY-U00309
    YM758 312752-85-5 99.71%
    YM758 is a "funny" If current channel (If channel) inhibitor.
    YM758
  • HY-U00344
    Theodrenaline 13460-98-5 98%
    Theodrenaline is a cardiac stimulant, also acts as an anti-hypotensive agent together with cafedrine.
    Theodrenaline
Cat. No. Product Name / Synonyms Application Reactivity